Bicocca Open Archive

Logo unimib boa
CARBONE, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.223
AS - Asia 7.060
EU - Europa 6.444
SA - Sud America 1.218
AF - Africa 129
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 5
Totale 26.089
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.995
SG - Singapore 2.725
IT - Italia 1.671
CN - Cina 1.543
HK - Hong Kong 1.190
RU - Federazione Russa 1.158
BR - Brasile 975
DE - Germania 962
VN - Vietnam 799
SE - Svezia 718
IE - Irlanda 607
GB - Regno Unito 415
IN - India 153
CA - Canada 147
AT - Austria 140
FR - Francia 137
KR - Corea 134
NL - Olanda 134
UA - Ucraina 126
AR - Argentina 111
FI - Finlandia 109
TR - Turchia 103
ID - Indonesia 92
BD - Bangladesh 61
PL - Polonia 58
MX - Messico 52
ZA - Sudafrica 49
JP - Giappone 48
DK - Danimarca 46
EC - Ecuador 44
IQ - Iraq 39
ES - Italia 35
MY - Malesia 26
BE - Belgio 21
VE - Venezuela 20
CO - Colombia 19
PK - Pakistan 17
PT - Portogallo 17
LT - Lituania 16
PY - Paraguay 15
IL - Israele 14
MA - Marocco 14
RO - Romania 13
UZ - Uzbekistan 13
EG - Egitto 12
SA - Arabia Saudita 12
TW - Taiwan 12
CZ - Repubblica Ceca 11
DZ - Algeria 11
JO - Giordania 11
AE - Emirati Arabi Uniti 9
AZ - Azerbaigian 9
CH - Svizzera 9
CL - Cile 9
UY - Uruguay 9
KE - Kenya 8
PE - Perù 8
BO - Bolivia 7
ET - Etiopia 7
SK - Slovacchia (Repubblica Slovacca) 7
AU - Australia 6
CR - Costa Rica 6
GR - Grecia 6
IR - Iran 6
OM - Oman 6
HN - Honduras 5
JM - Giamaica 5
MM - Myanmar 5
RS - Serbia 5
SN - Senegal 5
TH - Thailandia 5
TN - Tunisia 5
GH - Ghana 4
HU - Ungheria 4
LA - Repubblica Popolare Democratica del Laos 4
NP - Nepal 4
NZ - Nuova Zelanda 4
PA - Panama 4
AL - Albania 3
NO - Norvegia 3
QA - Qatar 3
SC - Seychelles 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BH - Bahrain 2
CG - Congo 2
GD - Grenada 2
GE - Georgia 2
GT - Guatemala 2
LU - Lussemburgo 2
MD - Moldavia 2
NG - Nigeria 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
ZW - Zimbabwe 2
AO - Angola 1
BB - Barbados 1
BN - Brunei Darussalam 1
Totale 26.066
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.274
Singapore 1.532
Hong Kong 1.169
Ashburn 853
Frankfurt am Main 712
Fairfield 634
Dublin 586
Chandler 569
Milan 521
Woodbridge 486
Wilmington 477
Houston 389
New York 358
Santa Clara 329
Hefei 296
Dallas 295
Chicago 266
Seattle 264
Dearborn 252
Ho Chi Minh City 246
Cambridge 224
Los Angeles 217
Beijing 215
Princeton 215
Hanoi 186
London 148
Jacksonville 147
Shanghai 133
Buffalo 121
Seoul 121
Vienna 114
Nanjing 109
Lawrence 103
Moscow 103
Rome 103
Altamura 101
São Paulo 95
The Dalles 91
San Diego 73
Munich 69
Jakarta 62
Boardman 57
Helsinki 47
Nuremberg 42
Florence 41
Warsaw 40
Council Bluffs 39
Toronto 39
Monza 38
Rio de Janeiro 37
Turin 35
Tokyo 34
Stockholm 32
Guangzhou 31
Salt Lake City 31
Andover 29
Lachine 29
Denver 28
Haiphong 28
Johannesburg 28
Brooklyn 27
Lissone 27
Nanchang 26
Phoenix 26
Poplar 26
Boston 24
Columbus 24
Orem 24
Pune 24
Bari 23
Biên Hòa 22
Hangzhou 22
Changsha 21
Ottawa 21
Tianjin 21
Brussels 20
Fremont 20
Amsterdam 19
Atlanta 19
Montreal 19
Mumbai 19
Quito 19
Da Nang 18
Genoa 18
Can Tho 17
Curitiba 17
Elk Grove Village 17
Guarulhos 17
Hebei 17
Paris 17
Bologna 16
Düsseldorf 16
Hải Dương 16
Penang 16
Tampa 16
Turku 16
Bergamo 15
Buenos Aires 15
Chennai 15
Mexico City 15
Totale 16.730
Salva come PNG Salva come JPEG
Nome #
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 515
The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis 407
A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude? 383
Exploring the landscape of steatotic liver disease in the general US population 371
Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison 341
Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid 340
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 333
Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak 306
Autoimmune liver disease, autoimmunity and liver transplantation 304
Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation 289
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 287
Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis 270
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 269
Liver Transplantation in Alcohol-Associated Hepatitis. Benefits and Limitations of Psychosocial Selection and Support in Alcohol Relapse. The Experience of a Tertiary Center in Italy 267
Precision medicine in primary biliary cholangitis 267
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study 266
Risk stratification in primary sclerosing cholangitis 265
A NOVEL MACHINE-LEARNING, COMMON VARIANTS-BASED APPROACH TO PREDICT PRIMARY BILIARY CHOLANGITIS 263
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls 259
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 258
Endocrinology and Metabolic Diseases (Including Diabetes) 254
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis 250
FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 250
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 246
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis 240
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 240
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis 238
Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group 237
THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 235
Autoimmune liver diseases 227
Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 227
New Therapeutic Targets in Autoimmune Cholangiopathies 227
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 224
Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis 223
Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland 221
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response 218
The mode of dexamethasone decoration influences avidin-nucleic-acid-nano-assembly organ biodistribution and in vivo drug persistence 217
Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature 216
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies 215
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach 213
The challenges of primary biliary cholangitis: What is new and what needs to be done 210
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 206
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 205
Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets 203
Prognostic models in primary biliary cholangitis 201
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 196
Artificial Intelligence and liver: Opportunities and barriers 194
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 194
Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers 192
Novel insights in primary biliary cholangitis (PBC) epidemiology using administrative records 189
A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis 189
Reply to: “A spotlight on natural killer cells in primary biliary cholangitis” 189
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis 182
Improving predictive accuracy in primary biliary cholangitis: A new genetic risk score 181
Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency 180
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 179
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe 178
Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study 177
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? 173
Genetics and epigenetics of primary biliary cirrhosis 173
Artificial intelligence for precision medicine in autoimmune liver disease 172
Leptin attenuates ischemia-reperfusion injury in the rat liver 172
Comprehensive review of autoantibodies in patients with hyper-IgM syndrome 169
Hepatitis C virus and nonliver solid organ transplantation 167
Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis 166
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma 166
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 165
Primary Sclerosing Cholangitis and Amyloid A Amyloidosis: Association or Coincidence? 164
Cell and organ bioengineering technology as applied to gastrointestinal diseases 162
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis 161
How regenerative medicine and tissue engineering may complement the available armamentarium in gastroenterology? 158
Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study 158
Deep learning helps discriminate between autoimmune hepatitis and primary biliary cholangitis 156
Treatment of PBC-A step forward 156
The immunobiology of female predominance in primary biliary cholangitis 156
Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)—A European Society of Organ Transplantation (ESOT) Consensus Statement 154
Late acute liver allograft rejection; A study of its natural history and graft survival in the current era 154
Cost of illness of Primary Biliary Cholangitis - a population-based study 153
Corrigendum to: “An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs” [J Hepatol 75 (2021) 572-581, (S0168827821003342), (10.1016/j.jhep.2021.04.055)] 152
Geoepidemiology, Genetic and Environmental Risk Factors for PBC 152
Treatment discontinuation with peg-interferon: What to consider 152
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 151
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 149
The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort 148
Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States 147
The "gut microbiota" hypothesis in primary sclerosing cholangitis 147
Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis 143
Primary sclerosing cholangitis: Burden of disease and mortality using data from the national rare diseases registry in Italy 143
An update on novel pharmacological agents for primary sclerosing cholangitis 142
Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis 142
Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history 141
Reply to: "Fatigue and liver transplantation in patients with primary biliary cirrhosis" 140
Liver Transplantation in the Clinic - Progress Made During the Last Three Decades 139
Primary Biliary Cholangitis: advances in management and treatment of the disease 137
The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study 136
Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation 135
An unusual endoscopic finding in a patient with melena: multiple gastric ulcers of regular shape 134
Calcium channel blockers or angiotensin-converting enzyme inhibitors for de novo hypertension after liver transplant: and the winner is …? 133
The application of artificial intelligence in hepatology: A systematic review 133
Toward precision medicine in primary biliary cholangitis 132
Totale 20.706
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.280
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.280
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.709 0 0 0 0 0 261 283 312 237 213 207 196
2021/20221.871 193 187 214 143 141 142 54 105 79 145 170 298
2022/20232.934 333 740 266 252 264 370 126 130 222 76 83 72
2023/20242.687 71 111 108 258 293 580 383 76 156 173 93 385
2024/20256.364 445 717 389 347 506 216 322 290 669 813 685 965
2025/20266.996 1.534 958 1.171 1.569 1.502 262 0 0 0 0 0 0
Totale 26.929